| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 01/09/2001 | US6171612 Gene therapy |
| 01/09/2001 | US6171609 Intravascular stent with cytoskeletal inhibitor; preventing stenosis or reducing restenosis |
| 01/09/2001 | US6171591 Recombinant nodavirus compositions and methods |
| 01/09/2001 | US6171583 Powdery iodine complexes |
| 01/09/2001 | US6171577 Accessible sulfhydryl group; and hexose moiety recognized by a mammalian liver receptor, wherein the hexose moiety is conjugated to the annexin. |
| 01/09/2001 | US6171294 Method and device for transdermal electrotransport delivery of fentanyl and sufentanil |
| 01/09/2001 | CA2204640C Conjugates of bdnf and nt-3 with a water-soluble polymer |
| 01/09/2001 | CA2060176C Small particle drug compositions |
| 01/06/2001 | CA2313339A1 Compositions containing fat-soluble substances in a carbohydrate matrix |
| 01/05/2001 | CA2314536A1 Stable microemulsions for the administration of fatty acids to humans or animals, and use of these microemulsions |
| 01/04/2001 | WO2001001140A1 Epitopes formed by non-covalent association of conjugates |
| 01/04/2001 | WO2001001139A2 Incorporation and appliations of biomolecular interactions within a carrier |
| 01/04/2001 | WO2001000883A1 Oligosaccharide-supplying compositions |
| 01/04/2001 | WO2001000832A1 Methods for making apo-2 ligand using divalent metal ions |
| 01/04/2001 | WO2001000709A1 Copolymers for the transfer of nucleic acids to the cell |
| 01/04/2001 | WO2001000708A1 Combinations for introducing nucleic acids into cells |
| 01/04/2001 | WO2001000654A2 Purification and stabilization of peptide and proteins in pharmaceutical agents |
| 01/04/2001 | WO2001000563A1 Amorphous nitric esters and their pharmaceutical compositions |
| 01/04/2001 | WO2001000549A2 Branched largely insatured fatty alcohols |
| 01/04/2001 | WO2001000247A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 01/04/2001 | WO2001000246A2 Hydrogels derived from chitosan and poly(ethylene glycol) |
| 01/04/2001 | WO2001000245A2 HUMANIZED ANTI-ErbB2 ANTIBODIES AND TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| 01/04/2001 | WO2001000244A2 METHODS OF TREATMENT USING ANTI-ErbB ANTIBODY-MAYTANSINOID CONJUGATES |
| 01/04/2001 | WO2001000243A1 Pharmaceutical complex |
| 01/04/2001 | WO2001000242A2 Polycation-based bioconjugates |
| 01/04/2001 | WO2001000241A2 Novel vector complexes and their use in gene therapy |
| 01/04/2001 | WO2001000240A2 Antitumor compound |
| 01/04/2001 | WO2001000238A1 TREATING PROSTATE CANCER WITH ANTI-ErbB2 ANTIBODIES |
| 01/04/2001 | WO2001000233A1 Vaccine compositions using antigens encapsulated within alginate microspheres for oral administration and preparation process thereof |
| 01/04/2001 | WO2001000230A1 Drug composition containing lecithin-modified superoxide dismutase |
| 01/04/2001 | WO2001000223A2 Multiple agent diabetes therapy |
| 01/04/2001 | WO2001000200A1 Injection-administered antiviral preparation |
| 01/04/2001 | WO2001000199A1 Compounds obtained from salvia species having antiviral activity |
| 01/04/2001 | WO2001000198A2 Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
| 01/04/2001 | WO2001000182A1 Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| 01/04/2001 | WO2001000181A2 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 01/04/2001 | WO2001000180A1 Self-emulsifying systems containing anticancer medicament |
| 01/04/2001 | WO2001000154A1 Gel-based cosmetic composition |
| 01/04/2001 | WO2001000139A1 Topical formulations comprising skin penetration agents and the use thereof |
| 01/04/2001 | WO2001000044A1 Novel chitosan-containing liquid compositions and methods for their preparation and use |
| 01/04/2001 | WO2001000041A2 Method of preparing protein agglomerates |
| 01/04/2001 | WO2001000038A1 An effervescent green tea extract formulation |
| 01/04/2001 | WO2000062769A3 Use of ap-1 activators to treat glaucoma and ocular hypertension |
| 01/04/2001 | WO2000054797A3 Pharmaceutical compositions comprising tgf-beta |
| 01/04/2001 | WO2000053236A3 Methods and compositions for targeted drug delivery |
| 01/04/2001 | DE19929758A1 Verwendung von vernetzten kationischen Polymeren in hautkosmetischen und dermatologischen Zubereitungen Use of crosslinked cationic polymers in skin cosmetic and dermatological preparations |
| 01/04/2001 | CA2727172A1 Methods of treatment using anti-erbb antibody-maytansinoid conjugates |
| 01/04/2001 | CA2377585A1 Methods for making apo-2 ligand using divalent metal ions |
| 01/04/2001 | CA2377211A1 Copolymers for transporting nucleic acids in the cell |
| 01/04/2001 | CA2377207A1 Combinations for introducing nucleic acids into cells |
| 01/04/2001 | CA2377204A1 Purification and stabilization of peptide and protein pharmaceutical agents |
| 01/04/2001 | CA2377132A1 Amorphous nitric esters and their pharmaceutical compositions |
| 01/04/2001 | CA2377110A1 Branched largely insatured fatty alcohols |
| 01/04/2001 | CA2377086A1 Self-emulsifying systems containing anticancer medicament |
| 01/04/2001 | CA2377074A1 Method for preparing polycation based bioconjugates suitable for transporting different kinds of active substances within the body |
| 01/04/2001 | CA2376922A1 Compounds obtained from salvia species having antiviral activity |
| 01/04/2001 | CA2376912A1 Compositions and methods of treating cancer using compositions comprising an inhibitor of endothelin receptor activity |
| 01/04/2001 | CA2376859A1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
| 01/04/2001 | CA2376714A1 Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers |
| 01/04/2001 | CA2375979A1 An effervescent green tea extract formulation |
| 01/04/2001 | CA2369839A1 Compositions of insulin and insulin-related peptide for treating diabetes |
| 01/03/2001 | EP1065233A1 Carrier polymers migrating into target organs and drug-containing polymers |
| 01/03/2001 | EP1064989A1 Emulsion comprising a volatile fluorinated oil and a silicone surfactant, cosmetic composition comprising the said emulsion and use of said surfactant to prepare a stable emulsion |
| 01/03/2001 | EP1064951A2 Erythropoietin derivatives |
| 01/03/2001 | EP1064950A1 Remedies for hepatitis |
| 01/03/2001 | EP1064946A2 Topical zinc compositions |
| 01/03/2001 | EP1064945A1 Therapeutic use of a helium/oxygen mixture, especially for treating asthma |
| 01/03/2001 | EP1064942A1 Sustained release preparations |
| 01/03/2001 | EP1064939A2 Transdermal systems for release of 5-HT3 receptor antagonists and use thereof for antiemetic treatment |
| 01/03/2001 | EP1064938A1 Pharmaceutical dosage forms for controlled release producing at least a timed pulse |
| 01/03/2001 | EP1064937A1 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 01/03/2001 | EP1064935A1 Solid thermoformable controlled-release pharmaceutical composition |
| 01/03/2001 | EP1064934A1 GRF-containing lyophilized pharmaceutical composition |
| 01/03/2001 | EP1064924A2 Use of cross-linked cationic polymers in skin cosmetic compositions and in dermatological compositions |
| 01/03/2001 | EP1064913A1 Microcaspules |
| 01/03/2001 | EP1064912A1 Microcapsules |
| 01/03/2001 | EP1064910A1 Microcapsules |
| 01/03/2001 | EP1064360A2 Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics |
| 01/03/2001 | EP1064346A1 High molecular weight polymer additive for coating and lubricating products |
| 01/03/2001 | EP1064026A1 Enhancement of intracellular delivery and tissue targeting of drugs and genes |
| 01/03/2001 | EP1064013A1 $i(IN VITRO) FORMATION OF CONGOPHILIC MALTESE-CROSS AMYLOID PLAQUES TO IDENTIFY ANTI-PLAQUE THERAPEUTICS FOR THE TREATMENT OF ALZHEIMER'S AND PRION DISEASES |
| 01/03/2001 | EP1063998A1 Medicament for preventing and/or treating a mammary carcinoma, containing a steroidal aromatase inhibitor |
| 01/03/2001 | EP1063992A1 Sulfurpenta fluorophenyl pyrazoles for controlling ectoparasitic infestations |
| 01/03/2001 | EP1063985A1 Benzoates derivatives for inhibiting angiogenesis |
| 01/03/2001 | EP1063983A1 Transdermal therapeutic system (tts) containing oxybutynin |
| 01/03/2001 | EP1063978A1 Method of treating neuroma pain |
| 01/03/2001 | EP1063977A1 Coated starch capsules and a process for producing them |
| 01/03/2001 | EP1063976A1 Tarch capsules containing microorganisms and/or polypeptides or proteins and a process for producing them |
| 01/03/2001 | EP1063975A1 Crosslinkable macromers bearing initiator groups |
| 01/03/2001 | EP1063972A1 Polymer based rapidly dissolving tablets and production processes thereof |
| 01/03/2001 | EP1063970A1 Slow release microcapsules |
| 01/03/2001 | EP1063969A1 Topical formulation of oil-in-water type as a carrier for providing a reduced irritant effect |
| 01/03/2001 | EP1063968A1 Improved compositions for inhalation |
| 01/03/2001 | EP1063942A1 Liquid polymeric compositions for controlled release of bioactive substances |
| 01/03/2001 | EP1063885A1 Xylitol compositions for treating upper respiratory conditions |
| 01/03/2001 | EP0828759B1 Process of high purity albumin production |
| 01/03/2001 | EP0785773B1 Ether lipid liposomes and their therapeutic use |
| 01/03/2001 | EP0722312B1 Pharmaceutical composition to enhance tissue healing and regeneration and application kit comprising it |
| 01/03/2001 | EP0702568B1 An emollient composition |
| 01/03/2001 | EP0610333B1 Treated apatite particles for medical diagnostic imaging |